Donor characteristics associated with mortality and GVHD for transplantation period 1988 to 2006
| Outcome . | HR (95% CI) . | P value . |
|---|---|---|
| Overall mortality* | ||
| Donor age, years | <.001 | |
| ≤32 | 1.00 | |
| 33 to 50 | 1.13 (1.05-1.20) | <.001 |
| >50 | 1.29 (1.14-1.46) | <.001 |
| Donor-recipient HLA-match | <.001 | |
| 8/8 HLA-match | 1.00 | |
| 7/8 HLA-match | 1.24 (1.15-1.34) | <.001 |
| 6/8 HLA-match | 1.62 (1.47-1.79) | <.001 |
| 5/8 or lower HLA-match | 1.89 (1.67-2.15) | <.001 |
| Blood group ABO match | .001 | |
| ABO matched | 1.00 | |
| ABO minor mismatch | 1.10 (1.01-1.18) | .002 |
| ABO major mismatch | 1.13 (1.05-1.21) | .001 |
| Nonrelapse mortality* | ||
| Donor age, years | .03 | |
| ≤32 | 1.00 | |
| 33 to 50 | 1.09 (1.01-1.19) | .03 |
| >50 | 1.20 (1.03-1.40) | .02 |
| Donor-recipient HLA-match | <.001 | |
| 8/8 HLA-match | 1.00 | |
| 7/8 HLA-match | 1.38 (1.26-1.51) | <.001 |
| 6/8 HLA-match | 1.85 (1.65-2.09) | <.001 |
| 5/8 or lower HLA-match | 2.16 (1.87-2.51) | <.001 |
| Donor sex and parity | <.001 | |
| Male | 1.00 | |
| Female, no pregnancies | 1.02 (0.91-1.14) | .75 |
| Female, 1 or more pregnancies | 1.29 (1.18-1.41) | <.001 |
| Relapse† | ||
| Donor age | .29 | |
| ≤32 y | 1.00 | |
| 33 to 50 y | 1.05 (0.95-1.16) | .35 |
| >50 y | 1.17 (0.95-1.42) | .13 |
| Donor sex and parity | .06 | |
| Male | 1.00 | |
| Female, no pregnancies | 0.96 (0.84-1.10) | .57 |
| Female, 1 or more pregnancies | 0.84 (0.74-0.95) | .007 |
| Grade 2 to 4 acute GVHD‡ | ||
| Donor age, years | .01 | |
| ≤32 | 1.00 | |
| 33 to 50 | 1.09 (1.02-1.16) | .01 |
| >50 | 1.17 (1.03-1.33) | .01 |
| Donor-recipient HLA-match | <.001 | |
| 8/8 HLA-match | 1.00 | |
| 7/8 HLA-match | 1.23 (1.14-1.32) | <.001 |
| 6/8 HLA-match | 1.26 (1.13-1.39) | <.001 |
| 5/8 or lower HLA-match | 1.46 (1.28-1.68) | <.001 |
| Chronic GVHD§ | ||
| Donor sex and parity | <.001 | |
| Male | 1.00 | |
| Female, no pregnancies | 1.01 (0.91-1.12) | .88 |
| Female, 1 or more pregnancies | 1.22 (1.11-1.34) | <.001 |
| Outcome . | HR (95% CI) . | P value . |
|---|---|---|
| Overall mortality* | ||
| Donor age, years | <.001 | |
| ≤32 | 1.00 | |
| 33 to 50 | 1.13 (1.05-1.20) | <.001 |
| >50 | 1.29 (1.14-1.46) | <.001 |
| Donor-recipient HLA-match | <.001 | |
| 8/8 HLA-match | 1.00 | |
| 7/8 HLA-match | 1.24 (1.15-1.34) | <.001 |
| 6/8 HLA-match | 1.62 (1.47-1.79) | <.001 |
| 5/8 or lower HLA-match | 1.89 (1.67-2.15) | <.001 |
| Blood group ABO match | .001 | |
| ABO matched | 1.00 | |
| ABO minor mismatch | 1.10 (1.01-1.18) | .002 |
| ABO major mismatch | 1.13 (1.05-1.21) | .001 |
| Nonrelapse mortality* | ||
| Donor age, years | .03 | |
| ≤32 | 1.00 | |
| 33 to 50 | 1.09 (1.01-1.19) | .03 |
| >50 | 1.20 (1.03-1.40) | .02 |
| Donor-recipient HLA-match | <.001 | |
| 8/8 HLA-match | 1.00 | |
| 7/8 HLA-match | 1.38 (1.26-1.51) | <.001 |
| 6/8 HLA-match | 1.85 (1.65-2.09) | <.001 |
| 5/8 or lower HLA-match | 2.16 (1.87-2.51) | <.001 |
| Donor sex and parity | <.001 | |
| Male | 1.00 | |
| Female, no pregnancies | 1.02 (0.91-1.14) | .75 |
| Female, 1 or more pregnancies | 1.29 (1.18-1.41) | <.001 |
| Relapse† | ||
| Donor age | .29 | |
| ≤32 y | 1.00 | |
| 33 to 50 y | 1.05 (0.95-1.16) | .35 |
| >50 y | 1.17 (0.95-1.42) | .13 |
| Donor sex and parity | .06 | |
| Male | 1.00 | |
| Female, no pregnancies | 0.96 (0.84-1.10) | .57 |
| Female, 1 or more pregnancies | 0.84 (0.74-0.95) | .007 |
| Grade 2 to 4 acute GVHD‡ | ||
| Donor age, years | .01 | |
| ≤32 | 1.00 | |
| 33 to 50 | 1.09 (1.02-1.16) | .01 |
| >50 | 1.17 (1.03-1.33) | .01 |
| Donor-recipient HLA-match | <.001 | |
| 8/8 HLA-match | 1.00 | |
| 7/8 HLA-match | 1.23 (1.14-1.32) | <.001 |
| 6/8 HLA-match | 1.26 (1.13-1.39) | <.001 |
| 5/8 or lower HLA-match | 1.46 (1.28-1.68) | <.001 |
| Chronic GVHD§ | ||
| Donor sex and parity | <.001 | |
| Male | 1.00 | |
| Female, no pregnancies | 1.01 (0.91-1.12) | .88 |
| Female, 1 or more pregnancies | 1.22 (1.11-1.34) | <.001 |
Model adjusted for recipient age, performance score, recipient cytomegalovirus serostatus, disease and disease status, and transplant period.
Model adjusted for performance score and disease and disease status.
Model adjusted for disease, graft type, GVHD prophylaxis, conditioning regimen intensity, and transplant period.
Model adjusted for patient age, disease, graft type, and GVHD prophylaxis.